South Australian Neonatal Medication Guidelines

# neostigmine 0.5mg/mL injection

© Department of Health, Government of South Australia. All rights reserved.



#### South Australian Neonatal Medication Guidelines

# neostigmine 0.5mg/mL injection

© Department of Health, Government of South Australia. All rights reserved.

#### **Dose and Indications**

1mg = 1000micrograms

Write all doses in micrograms

#### **Reversal of Neuromuscular Blockade**

(e.g. from pancuronium, vecuronium)

#### Intravenous

50micrograms/kg/dose, in addition to *atropine* (see atropine dosing guidelines), **in separate syringes** 

#### **Myasthenia Gravis**

Consult Neurologist prior to initiating treatment

#### Test dose - Intramuscular

150micrograms/kg

#### Short Term Management - Intramuscular / Subcutaneous

40micrograms/kg (30 minutes before a feed) every 6 to 8 hours increasing the dose on clinical response.

Obtain specialist advice for long term use or oral therapy.

# Preparation and Administration

#### Intravenous or Intramuscular or Subcutaneous

Dose	50micrograms	100micrograms	200micrograms	300micrograms	400micrograms	ì
Volume	0.1mL	0.2mL	0.4mL	0.6mL	0.8mL	ı

Intravenous give undiluted over 1 minute.

Intramuscular and subcutaneous give undiluted.

Discard remaining solution

# Compatible Fluids

Glucose 5%, glucose 10%, glucose/sodium chloride solutions, sodium chloride 0.9%.



ISBN number: Endorsed by: Contact: 978-1-74243-417-9 South Australian Maternal & Neonatal Clinical Network South Australian Neonatal Medication Guidelines Workgroup at: NeoMed@health.sa.gov.au Page 2 of 3

### South Australian Neonatal Medication Guidelines

# neostigmine 0.5mg/mL injection

© Department of Health, Government of South Australia. All rights reserved.

#### **Adverse Effects**

#### Common

Increased salivation, vomiting, diarrhoea, abdominal cramps

#### Infrequent

Rash, anaphylaxis

**Over treatment** may lead to cholinergic crisis with increased cholinergic effects (e.g. excessive sweating, miosis, nystagmus, bradycardia, hypotension, increased muscle weakness leading to fasciculation and paralysis), central nervous system effects (e.g. ataxia, seizures, agitation and coma) and respiratory failure

Atropine is used to control side effects

### Monitoring

Respiratory and cardiovascular status

#### **Practice Points**

With large doses or intravenous injections, bradycardia may occur, consequently, simultaneous parenteral administration of atropine sulfate (in separate syringe) may be advisable. Atropine should always be available to counteract severe cholinergic reactions.

## Version control and change history

PDS reference: OCE use only

Version	Date from	Date to	Amendment	
1.0	November 2012	current	Original version	



ISBN number:

Endorsed by: Contact: